Privia Health Group, Inc. PRVA
We take great care to ensure that the data presented and summarized in this overview for Privia Health Group, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PRVA
View all-
Black Rock Inc. New York, NY17.3MShares$368 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.9MShares$254 Million0.0% of portfolio
-
Durable Capital Partners LP Bethesda, MD9.09MShares$194 Million1.35% of portfolio
-
Wellington Management Group LLP Boston, MA5.44MShares$116 Million0.02% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.35MShares$114 Million0.06% of portfolio
-
Riverbridge Partners LLC5.15MShares$110 Million1.26% of portfolio
-
State Street Corp Boston, MA4.2MShares$89.4 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA3.34MShares$71 Million0.04% of portfolio
-
Geode Capital Management, LLC Boston, MA2.39MShares$50.9 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.34MShares$28.4 Million0.0% of portfolio
Latest Institutional Activity in PRVA
Top Purchases
Top Sells
About PRVA
Privia Health Group, Inc. operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings. It offers technology and population health tools to enhance independent providers' workflows; management services organization that enable providers to focus on their patients by reducing administrative work; single-TIN medical group that facilitates payer negotiation, clinical integration and alignment of financial incentives; accountable care organization, which engage patients, reduce inappropriate utilization, and enhance coordination and patient quality metrics to drive value-based care; and network for purchasers and payers that enable providers to connect with new patient populations and create custom contracts. The company was founded in 2007 and is headquartered in Arlington, Virginia. Privia Health Group, Inc. was a former subsidiary of Brighton Health Group Holdings, LLC.
Insider Transactions at PRVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 21
2024
|
Thomas A Mc Carthy Director |
BUY
Bona fide gift
|
Indirect |
41,487
+50.0%
|
-
|
Aug 21
2024
|
Thomas A Mc Carthy Director |
SELL
Bona fide gift
|
Direct |
41,487
-78.86%
|
-
|
Aug 21
2024
|
Matthew Shawn Morris Director |
BUY
Bona fide gift
|
Indirect |
11,998
+50.0%
|
-
|
Aug 21
2024
|
Matthew Shawn Morris Director |
SELL
Bona fide gift
|
Indirect |
11,998
-49.0%
|
-
|
Jun 11
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
364
+0.01%
|
$5,824
$16.5 P/Share
|
May 29
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
5,306
+0.09%
|
$84,896
$16.5 P/Share
|
May 24
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
4,280
+0.07%
|
$68,480
$16.49 P/Share
|
May 23
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
172,642
+2.91%
|
$2,762,272
$16.28 P/Share
|
May 23
2024
|
Thomas A Mc Carthy Director |
BUY
Open market or private purchase
|
Direct |
10,000
+15.97%
|
$160,000
$16.37 P/Share
|
May 22
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
102,229
+1.8%
|
$1,635,664
$16.43 P/Share
|
May 22
2024
|
Jaewon Ryu Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+26.89%
|
-
|
May 22
2024
|
Pamela O Kimmet Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+39.12%
|
-
|
May 22
2024
|
Thomas A Mc Carthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+20.7%
|
-
|
May 22
2024
|
David P King Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+24.7%
|
-
|
May 22
2024
|
Patricia Anne Maryland Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+24.7%
|
-
|
May 22
2024
|
Nancy G Cocozza Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+30.0%
|
-
|
May 22
2024
|
David S Wichmann Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+39.12%
|
-
|
May 22
2024
|
William M Sullivan Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,124
+24.7%
|
-
|
May 21
2024
|
Adam Boehler Director |
BUY
Open market or private purchase
|
Indirect |
277,565
+4.81%
|
$4,441,040
$16.17 P/Share
|
May 10
2024
|
Parth Mehrotra Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,869
-5.3%
|
$235,773
$17.88 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 320K shares |
---|---|
Exercise of conversion of derivative security | 15K shares |
Bona fide gift | 53.5K shares |
Open market or private purchase | 572K shares |
Open market or private sale | 166K shares |
---|---|
Bona fide gift | 65.5K shares |